TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three ended March 31, 2024, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com.
Dan Matlow, CEO of VitalHub, commented on the quarter’s success, stating, “We are thrilled to report that VitalHub has kicked off 2024 with outstanding momentum, achieving a 21% increase in revenue, which rose to $15.3 million, up from $12.6 million in Q1 last year. Our focus on driving operational excellence and expanding our solution offerings continues to yield significant financial benefits and value for our shareholders. Our growth strategy, underpinned by both organic initiatives and strategic acquisitions, has effectively increased our Annual Recurring Revenue (ARR) by 21% to $47.8 million. This growth is a testament to our strong market position and our team's dedication to delivering innovative solutions that meet the evolving needs of healthcare providers. In Q1, we achieved a gross profit of 81%, reflecting our ability to scale efficiently while improving our cost structure. This resulted in a 56% increase in EBITDA to $3.1 million, and a notable increase in adjusted EBITDA, which rose to $4.0 million or 27% of revenue, compared to $2.9 million or 23% of revenue in Q1 last year. Our disciplined approach to cash management enabled us to end the quarter with a healthy cash balance of $33.3 million, after having made significant investments in growth initiatives and the purchase of Bookwise. In addition, when you add our recent financing, the Company now has in excess of $70 million in cash.”
Matlow concluded, “As we move through 2024, VitalHub is well-positioned to continue our growth trajectory. We remain focused on expanding our reach in existing markets, exploring new opportunities, and enhancing our product portfolio through innovation and strategic mergers and acquisitions. Our strong financial position supports our ambitious growth plans and our commitment to leading the digital transformation in healthcare.”
VitalHub Corp’s quarterly investor conference call will take place on Friday, May 10, 2024, at 9:00AM EST.
To register for the call, please visit:
https://us02web.zoom.us/webinar/register/WN_cauJ_EXXTKqJuMRFFeBKYw
First Quarter 2024 Highlights
(1) The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions of the renewable software license fees and maintenance services.
(2) Non-IFRS measure.
SELECTED FINANCIAL INFORMATION | |||||
Three months ended | |||||
March 31, 2024 | % Revenue | March 31, 2023 | % Revenue | Change | |
$ | $ | % | |||
Revenue | 15,256,791 | 100% | 12,595,174 | 100% | 21% |
Cost of sales | 2,973,692 | 19% | 2,471,877 | 20% | (20%) |
Gross profit | 12,283,099 | 81% | 10,123,297 | 80% | 21% |
Operating expenses | |||||
General and administrative | 3,191,857 | 21% | 3,611,092 | 29% | 12% |
Sales and marketing | 1,696,464 | 11% | 1,281,665 | 10% | (32%) |
Research and development | 3,418,122 | 22% | 2,520,021 | 20% | (36%) |
Depreciation of property and equipment | 77,830 | 1% | 75,283 | 1% | (3%) |
Depreciation of right-of-use assets | 106,762 | 1% | 95,907 | 1% | (11%) |
Share-based compensation | 348,579 | 2% | 277,684 | 2% | (26%) |
Foreign currency gain | (68,276) | (0%) | (213,261) | (2%) | 68% |
Other income and expenses | |||||
Amortization of intangible assets | 1,106,542 | 7% | 1,054,247 | 8% | (5%) |
Business acquisition, restructuring and integration costs | 583,334 | 4% | 658,349 | 5% | 11% |
Loss on change in fair value of contingent consideration | 14,003 | 0% | - | 0% | (100%) |
Interest expense and accretion (net of interest income) | (184,807) | (1%) | (38,987) | (0%) | 374% |
Interest expense from lease liabilities | 13,794 | 0% | 20,869 | 0% | 34% |
Current and deferred income taxes | 660,429 | 4% | 618,260 | 5% | (7%) |
Net income | 1,318,466 | 9% | 162,168 | 1% | 713% |
EBITDA (Non-IFRS measure) | 3,099,016 | 20% | 1,987,747 | 16% | 56% |
Adjusted EBITDA (Non-IFRS measure) | 4,044,932 | 27% | 2,923,780 | 23% | 38% |
Annual recurring revenue (Non-IFRS measure) | 47,834,002 | 39,634,517 | 21% | ||
Term licences, maintenance and support revenue | 12,465,062 | 82% | 9,997,484 | 79% | 25% |
As at | |||||
March 31, 2024 | December 31, 2023 | ||||
$ | $ | ||||
Deferred revenue | 25,383,782 | 21,049,975 | |||
Cash balance | 33,315,264 | 33,480,018 |
ABOUT VITALHUB
Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.
VitalHub is a leading software company dedicated to empowering Health and Human Services providers. Our clients include hospitals, regional health authorities, mental health and addictions services providers for children and adults, long-term care facilities, home health agencies, correctional services, and community and social services providers.
VitalHub’s comprehensive suite of SaaS solutions include:
The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.
VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 400 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol "VHIBF".
CAUTIONARY STATEMENT
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$10.81 |
Daily Change: | -0.12 -1.10 |
Daily Volume: | 112,898 |
Market Cap: | C$549.690M |
November 13, 2024 October 30, 2024 August 08, 2024 July 30, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB